At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed follicle center cell lymphoma (WHO grade 1, 2, or 3a)
- ✓CD20 antigen expression confirmed by institutional flow cytometry or immunohistochemistry
- ✓Prior rituximab treatment (alone or with chemotherapy)
- ✓Time to progression ≥6 months from last rituximab dose
- ✕CNS involvement by lymphoma
- ✕HIV infection
- ✕Active second malignancy (except non-melanoma skin cancers)
- ✕Recent DVT/PE within 3 months of study entry
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory
In Brief
A Phase 2 clinical trial evaluating rituximab and lenalidomide for Lymphoma. Completed, enrolled 97 participants across 79 sites.
Detailed Summary
Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide may also stop the growth of non-Hodgkin's lymphoma by blocking blood flow to the cancer. Giving rituximab together with lenalidomide may kill more cancer cells. This randomized phase II trial is studying how well rituximab and/or lenalidomide work in treating patients with follicular non-Hodgkin's lymphoma that is not refractory to rituximab.
Study Details
Timeline
Interventions
Given IV
Given orally